231 related articles for article (PubMed ID: 19254831)
1. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Ausch C; Buxhofer-Ausch V; Olszewski U; Hinterberger W; Ogris E; Schiessel R; Hamilton G
Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
3. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
[TBL] [Abstract][Full Text] [Related]
4. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
[TBL] [Abstract][Full Text] [Related]
5. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
Olofsson MH; Cummings J; Fayad W; Brnjic S; Herrmann R; Berndtsson M; Hodgkinson C; Dean E; Odedra R; Wilkinson RW; Mundt KE; Busk M; Dive C; Linder S
Cancer Biomark; 2009; 5(3):117-25. PubMed ID: 19407366
[TBL] [Abstract][Full Text] [Related]
6. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Linder S; Olofsson MH; Herrmann R; Ulukaya E
Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C.
Yilmaz Y; Dolar E; Ulukaya E; Akgoz S; Keskin M; Kiyici M; Yerci O; Oral AY; Gul CB; Gurel S; Nak SG; Gulten M
Med Sci Monit; 2009 Apr; 15(4):CR189-93. PubMed ID: 19333204
[TBL] [Abstract][Full Text] [Related]
8. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
[TBL] [Abstract][Full Text] [Related]
9. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study.
Demiray M; Ulukaya EE; Arslan M; Gokgoz S; Saraydaroglu O; Ercan I; Evrensel T; Manavoglu O
Cancer Invest; 2006 Nov; 24(7):669-76. PubMed ID: 17118776
[TBL] [Abstract][Full Text] [Related]
10. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
Cummings J; Ranson M; Butt F; Moore D; Dive C
Cancer Chemother Pharmacol; 2007 Nov; 60(6):921-4. PubMed ID: 17333190
[TBL] [Abstract][Full Text] [Related]
11. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation.
Yagmur E; Trautwein C; Leers MP; Gressner AM; Tacke F
Clin Biochem; 2007 Jun; 40(9-10):651-5. PubMed ID: 17306787
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
Müller V; Stahmann N; Riethdorf S; Rau T; Zabel T; Goetz A; Jänicke F; Pantel K
Clin Cancer Res; 2005 May; 11(10):3678-85. PubMed ID: 15897564
[TBL] [Abstract][Full Text] [Related]
14. Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas.
Brandt D; Volkmann X; Anstätt M; Länger F; Manns MP; Schulze-Osthoff K; Bantel H
Eur J Cancer; 2010 May; 46(8):1464-73. PubMed ID: 20202824
[TBL] [Abstract][Full Text] [Related]
15. Serum M30 levels are associated with survival in advanced gastric carcinoma patients.
Yaman E; Coskun U; Sancak B; Buyukberber S; Ozturk B; Benekli M
Int Immunopharmacol; 2010 Jul; 10(7):719-22. PubMed ID: 20362077
[TBL] [Abstract][Full Text] [Related]
16. Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients.
Ausch C; Buxhofer-Ausch V; Olszewski U; Schiessel R; Ogris E; Hinterberger W; Hamilton G
J Gastrointest Surg; 2009 Nov; 13(11):2020-6. PubMed ID: 19727975
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair protein MSH2, cytokeratin 18 and cytokeratin 20 expression: clinicopathological correlation and prognostic value in colorectal cancer patients.
González JJ; Bernardo CG; Sanz L; Fresno MF; Barbón E; Noval JG; Martínez E
Hepatogastroenterology; 2007 Dec; 54(80):2266-71. PubMed ID: 18265645
[TBL] [Abstract][Full Text] [Related]
19. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Nagel M; Schulz J; Maderer A; Goepfert K; Gehrke N; Thomaidis T; Thuss-Patience PC; Al-Batran SE; Hegewisch-Becker S; Grimminger P; Galle PR; Möhler M; Schattenberg JM
Tumour Biol; 2018 Mar; 40(3):1010428318764007. PubMed ID: 29534639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
